Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates (Q27851482)

From Wikidata

Jump to navigation Jump to search

scientific article

Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates

Language	Label	Description	Also known as
English	Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates	scientific article	Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates

Statements

scholarly article

1 reference

13 November 2016

Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates (English)

1 reference

13 November 2016

dasatinib monohydrate

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Katherine Stemke-Hale

object named as

Katherine Stemke-Hale

3

0 references

Giovanni M. Pavan

object named as

Giovanni M Pavan

6

0 references

Maurizio Fermeglia

object named as

Maurizio Fermeglia

7

0 references

object named as

Sabrina Pricl

5

0 references

Alexander J. Lazar

object named as

Alexander J Lazar

4

0 references

14

object named as

Patrick Hwu

0 references

Gordon B. Mills

15

object named as

Gordon B Mills

0 references

author name string

Scott E Woodman

1

0 references

Jonathan C Trent

2

0 references

Y N Vashisht Gopal

8

0 references

Dan Yang

9

0 references

Donald A Podoloff

10

0 references

Doina Ivan

11

0 references

Kevin B Kim

12

0 references

Nicholas Papadopoulos

13

0 references

Michael A Davies

16

0 references

publication date

August 2009

0 references

Molecular Cancer Therapeutics

0 references

8

0 references

8

0 references

2079-85

0 references

Major response to imatinib mesylate in KIT-mutated melanoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3346953

20 March 2017

L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3346953

20 March 2017

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3346953

20 March 2017

Mutations of the BRAF gene in human cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3346953

20 March 2017

Distinct sets of genetic alterations in melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3346953

7 April 2017

Imatinib targeting of KIT-mutant oncoprotein in melanoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3346953

29 September 2017

Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3346953

29 September 2017

A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3346953

29 September 2017

A novel AKT3 mutation in melanoma tumours and cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3346953

29 September 2017

Phase II trial of imatinib mesylate in patients with metastatic melanoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3346953

29 September 2017

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3346953

29 September 2017

Point mutations of protein kinases and individualised cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3346953

29 September 2017

Somatic activation of KIT in distinct subtypes of melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3346953

29 September 2017

Lack of clinical efficacy of imatinib in metastatic melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3346953

29 September 2017

Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3346953

29 September 2017

Management of cutaneous melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3346953

29 September 2017

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3346953

29 September 2017

KIT gene mutations and copy number in melanoma subtypes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3346953

27 November 2018

Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3346953

27 November 2018

Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3346953

27 November 2018

C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3346953

27 November 2018

Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3346953

27 November 2018

Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3346953

27 November 2018

Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3346953

27 November 2018

KIT overexpression and amplification in gastrointestinal stromal tumors (GISTs).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3346953

27 November 2018

KIT/Val654 Ala receptor detected in one imatinib-resistant GIST patient.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3346953

27 November 2018

Prevalence of KIT expression in human tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3346953

27 November 2018

Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19671763

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

BRAF and c-kit gene copy number in mutation-positive malignant melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19671763

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19671763

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27851482&oldid=1998768332"